Combination of Topical Use of a Thrombin-based Hemostatic Matrix and Tranexamic Acid Does Not Have a Synergic Effect on Reducing Postoperative Blood Loss in Minimally Invasive Total Knee Arthroplasty. A Prospective Randomized Controlled Study
Abstract BackgroundThere is limited information regarding the blood-conservation effect of combined topical tranexamic acid (TXA) and thrombin-based hemostatic matrix (TBHM) in total knee arthroplasty (TKA). This study is to evaluate whether there is synergic effect of combined use of TXA and TBHM to reduce blood loss during TKA.Material and MethodsSixty-nine patients (69 knees) who underwent primary TKA were randomly assigned into a TXA group (n = 34), who received intra-articular administration of 3g of TXA in 60mL saline, and a TXA + TBHM group (n = 35), who received intra-articular TBHM and TXA (3g) in 60mL saline after TKA. The primary outcomes were total blood loss (TBL) and postoperative hemoglobin (Hb) level. Secondary outcomes included the transfusion rate and the incidence of venous thromboembolism (VTE).ResultsThe mean TBL in the TXA + TBHM group was 678 ± 203mL , which was similar to that in the TXA only group at 733 ± 217mL (p= 0.276). There were no differences in the postoperative Hb level between the two groups. The transfusion rate was similar in the TXA + TBHM group and the TXA only group (2.9% versus 0%, p= 0.242). No patients in either group developed VTE within 3 months.ConclusionsOur prospective randomized controlled study did not show a synergic blood-conservation effect of combined use of topical TBHM and TXA in patients undergoing TKA. Further investigation with a larger sample size may be required.Trial registration: ClinicalTrials.gov, NCT03328832. Registered Oct 30 2017, http://clinicaltrials.gov/ct/show/NCT03328832?order=1